Literature DB >> 26892645

Outcomes for Management of Lichen Sclerosus Urethral Strictures by 3 Different Techniques.

Chintan K Patel1, Jill C Buckley2, Leonard N Zinman1, Alex J Vanni3.   

Abstract

OBJECTIVE: To evaluate the intermediate-term outcomes from a large, single institution series of patients with lichen sclerosus (LS) who underwent surgical management of their urethral strictures.
MATERIALS AND METHODS: We retrospectively reviewed 79 patients who underwent surgical management of their LS urethral strictures from 2003 to 2014, comparing outcomes of patients undergoing a single-stage buccal mucosa graft (BMG) urethroplasty, 2-stage BMG urethroplasty, or perineal urethrostomy (PU). Demographic and surgical outcomes data were collected for all patients.
RESULTS: Of the 79 patients, the mean follow-up was 32.4 months, mean age was 50.1 years, and the mean body mass index was 35.7, with morbid obesity (body mass index > 35) in 48% of the cohort. The mean stricture length was 9.6 cm (1.5-21 cm), with 62% of patients having a bulbopendulous stricture. Of the 37 patients who were planned for a 2-stage BMG urethroplasty, 9 (24%) patients had stricture recurrence or recurrent LS in the first-stage BMG. Single-stage BMG urethroplasty was performed in 20 patients with a mean stricture length of 9.47 cm (4-21 cm) and a success rate of 75%. Fourteen patients from the cohort received a PU as the primary treatment, with a success rate of 93%.
CONCLUSION: Management of LS strictures continues to pose challenges to the reconstructive surgeon due to the high rate of stricture recurrence and often progression. Patients undergoing single-stage or 2-stage reconstruction often require revision and must be carefully observed for recurrent urethral stricture. PU offers the highest degree of success and should be considered for all patients.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 26892645     DOI: 10.1016/j.urology.2015.11.057

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  7 in total

Review 1.  Refractory Urethral Stricture Management: Indications for Alternative Grafts and Flaps.

Authors:  Alison C Levy; Alex J Vanni
Journal:  Curr Urol Rep       Date:  2018-02-26       Impact factor: 3.092

Review 2.  Current treatment of lichen sclerosus and stricture.

Authors:  Amanda S J Chung; Oscar A Suarez
Journal:  World J Urol       Date:  2019-12-05       Impact factor: 4.226

Review 3.  What is the role of single-stage oral mucosa graft urethroplasty in the surgical management of lichen sclerosus-related stricture disease in men? A systematic review.

Authors:  Francesco Esperto; Wesley Verla; Achilles Ploumidis; Rachel Barratt; Roberto La Rocca; Nicolaas Lumen; Yuhong Yuan; Felix Campos-Juanatey; Tamsin Greenwell; Francisco Martins; Nadir Osman; Silke Riechardt; Marjan Waterloos; Konstantinos Dimitropoulos
Journal:  World J Urol       Date:  2021-08-26       Impact factor: 4.226

4.  Versatile algorithmic midline approach to perineal urethrostomy for complex urethral strictures.

Authors:  Maxim J McKibben; Alexander T Rozanski; Joceline S Fuchs; Varun Sundaram; Allen F Morey
Journal:  World J Urol       Date:  2018-10-17       Impact factor: 4.226

5.  Role of urethral plate and fossa navicularis biopsies in the detection of balanitis xerotica obliterans in boys undergoing redo hypospadias repair.

Authors:  Mohamed Sultan; Mohamed El-Shazly; Eid Elsherif; Sheren Younes; Mohamed Selim
Journal:  Arab J Urol       Date:  2017-09-15

6.  Buccal mucosal graft urethroplasty in men-risk factors for recurrence and complications: a third referral centre experience in anterior urethroplasty using buccal mucosal graft.

Authors:  Marco Spilotros; Neha Sihra; Sachin Malde; Mahreen H Pakzad; Rizwan Hamid; Jeremy L Ockrim; Tamsin J Greenwell
Journal:  Transl Androl Urol       Date:  2017-06

7.  Long-term outcomes for 2-stage urethroplasty: an analysis of risk factors for urethral stricture recurrence.

Authors:  James R Furr; Eric S Wisenbaugh; Joel Gelman
Journal:  World J Urol       Date:  2021-04-03       Impact factor: 4.226

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.